Empagliflozin For Use In Treating Alport Syndrome
Patent No. EP3826642 (titled "Empagliflozin For Use In Treating Alport Syndrome") was filed by Boehringer Ingelheim on Jul 23, 2019. The application was issued on Jun 11, 2025.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3826642
- Application Number
- EP19742218A
- Filing Date
- Jul 23, 2019
- Status
- Granted And Under Opposition
- Apr 4, 2025
- Publication Date
- Jun 11, 2025
- External Links
- Slate, Register , Google Patents